摘要
目的探讨社区获得性肺炎的初始治疗方案及药学监护。方法通过1例患者的用药失误对社区获得性肺炎的初始经验性治疗进行归纳和总结,总结药学监护点。结果该患者入院后未及时行支原体抗体检测,初始治疗给予头孢他啶联合利巴韦林,治疗后期更换为阿奇霉素联合头孢曲松及炎琥宁注射液,并在治疗过程中出现过敏反应。结论社区获得性肺炎的经验治疗应覆盖非典型病原体,临床药师应及时进行药学监护,防止不良反应的发生。
Objective To investigate the therapeutic methods and pharmaceutical care of community-acquired pneumonia. Methods Through analyzing medication errors, the primary therapeutic experiences of community-acquired pneu- monia were summarized. Results The patient didn＇t immediately take the mycoplasma body test after hospitalization. At the beginning of treatment, the doctor selected Ceftazidime and Ribavirin. At the last stage of treatment, the drugs were changed to Azithromycin, Ceftriaxone and Potassium Sodium Dehydroandroan drographolide Succinate for Injection. During the period of hospitalization, the patient appeared anaphylaxis. Conclusion We should empirically cover untypical pathogen in treating CAP. The clinical pharmacists should timely do pharmaceutical care in order to avoid the adverse drug reaction.
出处
《中国药物警戒》
2012年第5期290-292,共3页
Chinese Journal of Pharmacovigilance
关键词
社区获得性肺炎
不良反应
药学监护
community-acquired pneumonia
adverse reaction
pharmaceutical care
